PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies demonstrated that PCSK9 binds to the low-density lipoprotein (LDL) receptor directing it to its lysosomal degradation. Therefore, ca...

Full description

Bibliographic Details
Main Authors: Julius L. Katzmann, Ioanna Gouni-Berthold, Ulrich Laufs
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Physiology
Subjects:
PCSK9
LDL cholesterol
atherosclerosis
coronary artery disease
evolocumab
alirocumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2020.595819/full

Similar Items

Similar Items